Video & Transcript DataContr Research : 'biosimilars'
US
Us Congress 2025-2026 Regular Session
Business meeting to consider S.527, to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, S.1040, to amend the Federal Trade Commis Apr 3rd, 2025 at 09:15 am
Senate Judiciary Committee
Keywords:
drug competition, product hopping, generic drugs, biosimilars, federal regulations, FTC Act, patent, biological products, healthcare access, affordable prescriptions, Medicare, Federal Trade Commission, generic drugs, biosimilars, sham petitions, competition, public health, unfair competition, healthcare, pharmaceutical
Summary:
The meeting focused on addressing the high cost of prescription drugs and the abusive practices that contribute to elevated prices affecting American families. Several bills were presented, including proposals to end pay-for-delay deals and to enhance transparency in the operations of pharmacy benefit managers (PBMs). The discussion was notable for its emphasis on consumer protection and ensuring that cheaper generic drugs reach the market more effectively. Members expressed frustration over past attempts to pass similar legislation stalling in the Senate, leading to renewed efforts to push these bills forward.
TX
Texas 2025 - 89th Regular
Health and Human Services (Part I) Apr 9th, 2025
Senate Health & Human Services Committee
Transcript Highlights:
- A new drug comes out; Humira has a biosimilar that just came out.
- You know, Humira was $10,000 per injection, while the biosimilar, which is exactly the same, is about
Bills:
SB227, SB269, SB407, SB463, SB527, SB547, SB1283, SB1380, SB1383, SB1511, SB1640, SB1784, SB2069
Keywords:
school funding, education reform, state budget, property taxes, equity in education, healthcare policy, vaccines, exemptions, religious beliefs, public health, workplace violence, healthcare facilities, definition expansion, safety regulations, health and safety code, health insurance, anesthesia, pediatric dental services, coverage, medical necessity
Summary:
The meeting of the Health and Human Services Committee covered a variety of bills focused on improving health care access, patient protections, and enhancing oversight of health-related services. Key discussions were held around SB1640, which aims to broaden the scope of criminal history checks for Medicaid providers to enhance accountability and prevent fraud. Senator Hagenbooth explained the committee substitute, emphasizing the necessity of strengthening vetting processes within Medicaid programs. Additionally, SB1784 was introduced, which seeks to protect patients from unexpected medical debt collection practices by mandating advance written notices before debt collection actions are initiated. Discussion around this bill reflected a collective concern for transparency in medical billing and the financial wellbeing of patients.
TX
Texas 2025 - 89th Regular
Health and Human Services Apr 1st, 2025
Senate Health & Human Services Committee
Transcript Highlights:
- It could be something also to deal with, maybe a biosimilar
Bills:
SB331, SB883, SB926, SB1137, SB1138, SB1144, SB1151, SB1236, SB1270, SB1522, SB1869, SB2207, SB2422
Keywords:
healthcare, cost disclosure, transparency, administrative penalties, health facility compliance, COVID-19, off-label use, prescription drugs, patient access, medical standards, healthcare, insurance, physician ranking, incentives, fiduciary duty, health plan issuers, first responders, emergency response, group homes, local government
Summary:
The meeting centered on multiple significant legislative proposals aimed at healthcare reforms, notably focused on the operations of pharmacy benefit managers (PBMs) and their impact on local pharmacies. Senator Hughes led the discussion on SB1236, which aims to regulate PBMs to prevent anti-competitive practices that have led to the closure of numerous community pharmacies. Testimonies from various stakeholders, including pharmacists, highlighted the challenges posed by current PBM practices, such as aggressive audit tactics and contract terms that disadvantage small pharmacies. The bill was generally supported in the committee due to its potential to restore balance and fairness in pharmacy operations.
TX
Transcript Highlights:
- And after that, it becomes available to generics in the case of a synthetic drug or to biosimilars in
Keywords:
cremation, natural organic reduction, health and safety, environmental concerns, funeral services, medical licensing, physician graduates, healthcare access, occupational licensing, foreign medical graduates, cell-cultured protein, food safety, human consumption, agriculture, food labeling, healthcare workforce, advisory board, Texas Workforce Commission, resource guide, education collaboration
Summary:
The meeting of the public health committee focused on the pressing issue of opioid addiction in Texas, with a particular emphasis on House Bill 3717. Chairman Harris detailed the bill's intent to fund a grant program for Ibogaine clinical trials, framing it as a critical response to the ongoing opioid crisis. He shared poignant testimonies highlighting the struggles of families and veterans battling addiction and mental health issues. The conversation underscored the necessity of innovative treatments, like Ibogaine, which showed promising results in studies for reducing symptoms of withdrawal and PTSD.